In 2024/25 there were 140,000 fewer referrals for suspected bowel cancer than expected. The faecal immunochemical test (FIT) detects small amounts of blood in poo, which can be a sign of bowel cancer.

The treatment has been approved for NHS use, offering new hope to the nearly 12,000 people in England living with lupus ...

Dupilumab, a simple pre-filled pen that people inject themselves with every two weeks, is the first biologic that targets both the symptoms of COPD and an underlying cause of the disease. It brings ...

Thousands of people living with advanced prostate cancer will have access to a life-extending new treatment that can be taken at home from today (Friday, 23 January). NICE has recommended talazoparib ...

Evidence-based recommendations on natalizumab originator (Tysabri) and biosimilar (Tyruko) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy in adults.

NICE is unable to make a recommendation on concizumab (Alhemo) for treating haemophilia A or B in people 12 years and over with factor inhibitors. This is because the company did not provide an ...

NICE is unable to make a recommendation on pembrolizumab (Keytruda) with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma in adults. This ...

Accessed via the internet, the online self-help programme is for people who binge eat, particularly those with bulimia nervosa, binge eating disorder, and similar eating problems. It's designed for ...

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

An online therapy programme can be used to help people aged 16 and over with eating disorders whilst they wait for specialist NHS treatment, an independent NICE has said. As Sam Roberts prepared to ...

NICE has developed tools and resources, in association with relevant stakeholders, to help organisations put this guidance into practice. The evidence generation plan gives further information on the ...

Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer in adults after 2 or more anti-HER2 therapies. Next review: More ...